Previous studies suggest that approximately half of all BC tumors fall into the HER2-low category (8), with two-thirds scoring as IHC 1+ and one-third as IHC2+/ISH-, irrespective of HR status (12). This evidence concerns the gene ERBB2 and breast cancer.